Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pertuzumab - Genentech/Roche

Drug Profile

Pertuzumab - Genentech/Roche

Alternative Names: Anti-2C4 monoclonal antibody; Omnitarg; Perjeta; R-1273; RG-1273; rhuMab-2C4; rhuMAb2C4; Ro 436-8451/F01; RO-4368451-F01; RO4368451

Latest Information Update: 14 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech; Roche
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Japan Breast Cancer Research Group; Medica Scientia Innovation Research; Roche; West German Study Group
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Ovarian cancer
  • Phase II Brain metastases; Colorectal cancer
  • Phase I HER2 positive breast cancer
  • Discontinued Gastric cancer; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 05 Dec 2023 Updated efficacy data from the phase III APHINITY trial in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
  • 13 Nov 2023 Phase-I clinical trials in HER2-positive-breast-cancer (Early-stage disease, Metastatic disease, Combination therapy) (IV), prior to November 2023 (Genentech communications, November 2023)
  • 01 Nov 2023 MedSIR completes a phase-II trials in Breast cancer (Neoadjuvant therapy) in Belgium, France, Germany, Italy, Portugal, Spain, United Kingdom (IV) (NCT03161353) (EudraCT2016-002676-27)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top